medigraphic.com

2019, Number 2

<< Back Next >>

Rev Cuba Endoc 2019; 30 (2)

Quality of life in patients operated for endogenous hypercortisolism

Cabrera GM, Domínguez AE, Acosta CA, Turcios TSE, Ledón L, Bartolomé CJL, Mustelier M, Robles TE, Díaz SC

Language: Spanish
References: 25
Page: 1-18
PDF size: 608.75 Kb.


ABSTRACT

Introduction: Endogenous hypercortisolism causes changes in different areas of life and the perceived sense of well-being, which affects the quality of life. This should be taken into account in the patient comprehensive care.
Objectives: To describe the quality of life perceived in patients with endogenous hypercortisolism and to identify if there is a relationship between quality of life and some clinical and hormonal characteristics.
Methods: Cross-sectional study, 60 patients: group I (with endogenous hypercortisolism operated less than five years) and group II (people with clinical suspicion of endogenous hypercortisolism), age between 20 and 60 years. Quality of life questionnaires related to endogenous hypercortisolism were applied: CushingQoL and Tuebingen CD-25 and general, clinical and hormonal data collection form. Median (quantitative variables) and frequency in the qualitative ones were determined. The association of the score of questionnaires and quantitative variables were obtained by means of the Spearman correlation coefficient. The average score values were compared between categories of qualitative variables (clinical and hormonal categorized), using the U-Mann Whitney test; significant statistical difference was considered with p ≤ 0.05.
Results: The median score of the psycho-emotional domains, sexuality, social area, body area, and the sum of all domains were higher in group I. Sexuality (4.5), body area (6.0) and the sum of all domains (36.5) of group I vs. 1.0, 4.0 and 28.0 respectively (group II), of the Tuebingen CD-25 showed statistically significant differences, which is worse quality of life in group I. Using the CushingQoL, the median score of group I showed to be lower than in group II (54.1 vs. 74.0) there are statistically significant differences (p = 0.00), which shows worse quality of life in group I.
Conclusions: Endogenous hypercortisolism negatively affects the quality of life perceived in the group of operated patients, especially in the social, bodily, cognitive, sexual areas, and eating behaviour.


REFERENCES

  1. Susmeeta T, Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidem. 2015;7:281-93.

  2. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol. 2008;158:623-30.

  3. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewar PM, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526-40.

  4. Kuyken W, Orley J, Power M. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403-9.

  5. Hawn MT, Cook D, Deveney C, Sheppard BC. Quality of life after laparoscopic bilateral adrenalectomy for Cushing’s disease. Surg. 2002;132:1064-8.

  6. Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing’s disease: a 10-year experience. Ann Surg. 2007; 245:790-4.

  7. Van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, et al. Disease specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol. 2008;69:775-84.

  8. Alcalar N, Ozkan S, Kadioglu P. Evaluation of depression, quality of life and body image in patients with Cushing’s disease. Pituitary. 2013;16:333-40.

  9. Huguet I, Ntali G, Grossman A, Karavitaki N. Cushing’s disease – Quality of life, recurrence and long-term morbidity. Eur endocrinol. 2015;11(1):34-8.

  10. Milian M, Kreitschmann-Andermahr I, Siegel S, Kleist B, Führer-Sakel D, Honegger J, et al. Validation of the Tuebingen CD-25 inventory as a measure of postoperative health-related quality of life in patients treated for Cushing’s disease. Neuroendocrinol. 2015;102:60-7.

  11. Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson L, et al. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease. Eur J Endocrinol. 2014;171(1):89-98.

  12. Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T. The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25), part I: construction and psychometric properties. Clin Endocrinol. 2012;76:851-60.

  13. Badia X, Valassi E, Roset M, Webb SM. Disease-specific quality of life evaluation and its determinants in Cushing’s syndrome: what have we learnt? Pituitary. 2014;17:187-95. DOI 10.1007/s11102-013-0484.

  14. Ledón L, Agramonte A, Fabré BL, Hernández J. Impacto de la acromegalia y el síndrome de Cushing sobre la salud, una perspectiva vivencial. Rev Cubana Endocrinol. 2011;22(2):144-66.

  15. Ledón L, Fabré BL, García CT, Mendoza M, Agramonte A, Hernández J. Sexualidad de personas con acromegalia y síndrome de Cushing: diversidad de experiencias y aspectos psicosociales relacionados. Rev Cubana Endocrinol. 2017;28(1):1-20.

  16. García J. Apuntes sobre la calidad de vida: su carácter socioeconómico y su relación con la salud. Rev Cubana Invest Biomed. 2005;24:72-6.

  17. Santos A, Resmini E, Martínez-Momblán MA, Crespo I, Valassi E, Roset M, et al. Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. Eur J Endocrinol. 2012;167:337-42.

  18. Valassi E, Santos A, Yaneva M, Toth M, Strasburger Ch, Chanson P, et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165:383-92.

  19. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27:1066-70.

  20. Moldovan I, Katsaros E, Carr FN, Cooray D, Torralba K, Shinada S, et al. The patient reported outcomes in lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort. Lupus. 2011;20:1285-92.

  21. Vetter ML, Wadden TA, Lavenberg J, Moore RH, Volger S, Perez JL, et al. Relation of health-related quality of life to metabolic syndrome, obesity, depression and comorbid illnesses. Int J Obes. 2011;35:1087-94.

  22. Carluccio A, Sundaram NK, Chablani S, Amrock LG, Lambert JK, Post KD, et al. Predictors of quality of life in 102 patients with treated Cushing’s disease. Clin Endocrinol. 2015;82 (3):404-11.

  23. Tiemensma J, Kaptein AA, Pereira A, Smit J, Romijn J, Biermasz N. Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome. Eur J Endocrinol. 2011;165:527-35. DOI: 10.1530/EJE-11-0307.

  24. Aulinasa A, Valassi E, Susan W. Pronóstico del paciente tratado de síndrome de Cushing. Revisión. Endocrinol Nutr. 2014;61(1):52-61.

  25. Webb SM, Valassi E. Quality of Life in Cushing’s disease: A long-term issue? Ann Endocrinol. 2017;79(3):132-7. DOI 10.1016/j.ando.2018.03.007.




2020     |     www.medigraphic.com